Bristol-Myers Squibb Company (NYSE:BMY) received a $49.00 price target from investment analysts at BMO Capital Markets in a research note issued to investors on Thursday, October 26th. The firm currently has a “sell” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price would indicate a potential downside of 19.49% from the company’s previous close.
Several other research analysts have also commented on BMY. BidaskClub lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, July 3rd. Cowen and Company set a $65.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, July 10th. Jefferies Group LLC restated a “buy” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, July 12th. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 target price on the stock in a research note on Wednesday, July 12th. Finally, Deutsche Bank AG set a $55.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $64.93.
Bristol-Myers Squibb (NYSE:BMY) opened at $60.86 on Thursday. The firm has a market capitalization of $99,609.57, a P/E ratio of 20.56, a price-to-earnings-growth ratio of 2.40 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb has a 1-year low of $46.01 and a 1-year high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period last year, the firm earned $0.77 earnings per share. equities research analysts expect that Bristol-Myers Squibb will post 2.99 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Bristol-Myers Squibb Company (BMY) PT Set at $49.00 by BMO Capital Markets” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://ledgergazette.com/2017/11/13/bristol-myers-squibb-company-bmy-given-a-49-00-price-target-at-bmo-capital-markets.html.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.23% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Zeke Capital Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 96.3% in the third quarter. Zeke Capital Advisors LLC now owns 30,969 shares of the biopharmaceutical company’s stock valued at $1,974,000 after acquiring an additional 15,189 shares in the last quarter. Amalgamated Bank raised its stake in shares of Bristol-Myers Squibb by 2.0% in the third quarter. Amalgamated Bank now owns 193,806 shares of the biopharmaceutical company’s stock valued at $12,353,000 after acquiring an additional 3,719 shares in the last quarter. Farr Miller & Washington LLC DC raised its stake in shares of Bristol-Myers Squibb by 573.5% in the third quarter. Farr Miller & Washington LLC DC now owns 381,639 shares of the biopharmaceutical company’s stock valued at $24,326,000 after acquiring an additional 324,976 shares in the last quarter. Twin Capital Management Inc. raised its stake in shares of Bristol-Myers Squibb by 10.0% in the third quarter. Twin Capital Management Inc. now owns 208,347 shares of the biopharmaceutical company’s stock valued at $13,280,000 after acquiring an additional 18,976 shares in the last quarter. Finally, Cadence Capital Management LLC raised its stake in shares of Bristol-Myers Squibb by 8.1% in the third quarter. Cadence Capital Management LLC now owns 210,235 shares of the biopharmaceutical company’s stock valued at $13,400,000 after acquiring an additional 15,803 shares in the last quarter. Institutional investors and hedge funds own 69.51% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.